BeOne Medicines Ltd (HK:6160)
:6160
Want to see HK:6160 full AI Analyst Report?
6160 Stock Chart & Stats
HK$193.20
HK$5.50(5.26%)
At close: 4:00 PM EST
HK$193.20
HK$5.50(5.26%)
Day’s Range― - ―
52-Week RangeHK$144.10 - HK$229.40
Previous CloseN/A
Volume1.62M
Average Volume (3M)5.08M
Market Cap
HK$251.18B
Enterprise ValueHK$27.65B
Total Cash (Recent Filing)HK$4.83B
Total Debt (Recent Filing)HK$2.05B
Price to Earnings (P/E)59.4
Beta0.89
Next Earnings
Aug 21, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.37
Shares Outstanding1,426,363,900
10 Day Avg. Volume3,608,600
30 Day Avg. Volume5,076,742
Financial Highlights & Ratios
PEG Ratio-0.80
Price to Book (P/B)7.49
Price to Sales (P/S)6.10
P/FCF Ratio34.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$259.07Price Target Upside34.09% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)4.06
Revenue Forecast (FY)HK$50.73B
Bulls Say, Bears Say
Bulls Say
High ProfitabilitySustained very high gross margins and a clear EBIT and net income inflection provide durable operating leverage. High gross margins protect core profitability versus cyclical revenue swings and support reinvestment into R&D and commercialization over the next several quarters.
Robust Cash GenerationMaterial free cash flow and meaningful FCF growth indicate the business converts reported profits into cash, providing funding for trials, launches, and M&A without immediate external financing. Strong cash generation reduces refinancing risk and supports multi-quarter strategic initiatives.
Regulatory/Commercial ProgressAccelerated FDA approval for Beqalzi is a structural commercial milestone: it converts a late-stage asset into an addressable revenue stream, lowers binary clinical risk for that program, and enables commercialization scale and real-world data generation that can underpin sustained revenue growth.
Bears Say
Growth NormalizationRevenue deceleration from prior hyper-growth to single-digit TTM growth is a durable structural concern: the company must offset slower organic demand via new product launches or geographic expansion to sustain margins and cash flow, or profitability could become more reliant on cost discipline.
Rising LeverageDebt increased materially year-over-year, raising financial rigidity. Higher leverage reduces balance-sheet flexibility for funding trials, launches, or setbacks and elevates interest/ refinancing risk, especially if revenue growth slows or if additional capital is needed for pipeline advancement.
Cash Conversion LagOperating cash flow covering significantly less than accounting EBIT signals working-capital or timing drags. Persistent cash conversion shortfalls can constrain cash available for growth investments and amplify stress if margins or sales slow, making liquidity more sensitive to operational swings.
BeOne Medicines Ltd News
6160 FAQ
What was BeOne Medicines Ltd’s price range in the past 12 months?
BeOne Medicines Ltd lowest stock price was HK$144.10 and its highest was HK$229.40 in the past 12 months.
What is BeOne Medicines Ltd’s market cap?
BeOne Medicines Ltd’s market cap is HK$251.18B.
When is BeOne Medicines Ltd’s upcoming earnings report date?
BeOne Medicines Ltd’s upcoming earnings report date is Aug 21, 2026 which is in 77 days.
How were BeOne Medicines Ltd’s earnings last quarter?
BeOne Medicines Ltd released its earnings results on May 06, 2026. The company reported HK$1.181 earnings per share for the quarter, beating the consensus estimate of HK$0.879 by HK$0.302.
Is BeOne Medicines Ltd overvalued?
According to Wall Street analysts BeOne Medicines Ltd’s price is currently Undervalued.
Does BeOne Medicines Ltd pay dividends?
BeOne Medicines Ltd does not currently pay dividends.
What is BeOne Medicines Ltd’s EPS estimate?
BeOne Medicines Ltd’s EPS estimate is 1.
How many shares outstanding does BeOne Medicines Ltd have?
BeOne Medicines Ltd has 1,426,363,900 shares outstanding.
What happened to BeOne Medicines Ltd’s price movement after its last earnings report?
BeOne Medicines Ltd reported an EPS of HK$1.181 in its last earnings report, beating expectations of HK$0.879. Following the earnings report the stock price went up 2.941%.
Which hedge fund is a major shareholder of BeOne Medicines Ltd?
Currently, no hedge funds are holding shares in HK:6160
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
BeOne Medicines Ltd Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$259.07 (34.09% Upside)
HK$259.07 (34.09% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
39.37%
12-Months-Change
Fundamentals
Return on Equity
12.04%
Trailing 12-Months
Asset Growth
47.56%
Trailing 12-Months
Company Description
BeOne Medicines Ltd
BeiGene Ltd. is a global, science-driven biotechnology company focused on developing innovative and affordable medicines to improve treatment outcomes and access for patients worldwide. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.
6160 Stock 12 Month Forecast
Average Price Target
HK$259.07
▲(34.09% Upside)
Technical Analysis
Innovent Biologics
―
Wuxi Biologics (Cayman)
―
WuXi AppTec Co., Ltd. Class H
―
Hansoh Pharmaceutical Group Company Limited
―
Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
―
Options Prices
Currently, No data available
---